Lilly hails Alzheimer's win with donanemab, boasting 'significant slowing of decline'

The amyloid theory continues to grasp at life as Eli Lilly has unveiled new phase 2 data that can help by clearing these plaques out of the brain.

https://www.fiercebiotech.com/biotech/lilly-hails-alzheimer-s-win-donanemab-boasting-significant-slowing-decline